Detalles de la búsqueda
1.
Pharmacology of orismilast, a potent and selective PDE4 inhibitor.
J Eur Acad Dermatol Venereol
; 37(4): 721-729, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36527389
2.
Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets.
J Eur Acad Dermatol Venereol
; 37(4): 711-720, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36478476
3.
Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
Diabetes Obes Metab
; 21(7): 1706-1714, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30924579
4.
The rate of hyperglycemia and ketosis with insulin degludec-based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials.
Pediatr Diabetes
; 20(3): 314-320, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30666772
5.
The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
Diabetes Obes Metab
; 20(7): 1585-1592, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29451706
6.
Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes.
Diabetes Care
; 43(2): 398-404, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31658975
7.
Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK.
BMJ Open Diabetes Res Care
; 7(1): e000664, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31543973
8.
Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
Appl Health Econ Health Policy
; 17(5): 615-627, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31264138
9.
Clinical inertia in basal insulin-treated patients with type 2 diabetes - Results from a retrospective database study in Japan (JDDM 43).
PLoS One
; 13(9): e0198160, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30226870
10.
DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK.
Diabetes Ther
; 9(3): 1217-1232, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29713962
11.
Healthcare Resource Utilization and Costs Associated with Ketosis Events in Pediatric and Adult Patients with Type 1 Diabetes Mellitus in the UK.
Diabetes Ther
; 8(5): 1065-1078, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28905317
Resultados
1 -
11
de 11
1
Próxima >
>>